Your browser is no longer supported. Please, upgrade your browser.
Settings
INNT Innovate Biopharmaceuticals, Inc. daily Stock Chart
INNT [NASD]
Innovate Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own0.10% Shs Outstand36.08M Perf Week4.31%
Market Cap27.59M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float23.00M Perf Month-6.18%
Income-21.20M PEG- EPS next Q-0.13 Inst Own7.40% Short Float6.81% Perf Quarter-34.65%
Sales- P/S- EPS this Y89.60% Inst Trans-24.56% Short Ratio7.82 Perf Half Y-32.93%
Book/sh-0.09 P/B- EPS next Y-17.20% ROA-194.60% Target Price10.00 Perf Year-70.70%
Cash/sh0.25 P/C3.10 EPS next 5Y- ROE- 52W Range0.71 - 4.32 Perf YTD-66.90%
Dividend- P/FCF- EPS past 5Y25.50% ROI- 52W High-82.30% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.69% ATR0.06
Employees24 Current Ratio0.70 Sales Q/Q- Oper. Margin- RSI (14)42.27 Volatility5.95% 7.72%
OptionableYes Debt/Eq- EPS Q/Q68.70% Profit Margin- Rel Volume0.64 Prev Close0.77
ShortableYes LT Debt/Eq- EarningsNov 12 Payout- Avg Volume200.06K Price0.76
Recom2.00 SMA20-0.88% SMA50-12.51% SMA200-38.24% Volume127,603 Change-0.66%
Nov-18-19 12:32PM  How a merger could mean the 'next Salix' for Raleigh American City Business Journals
Nov-13-19 08:00AM  RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline PR Newswire
Oct-07-19 02:38PM  Triangle drugmaker plans merger with Israeli pharma -- what it means for Raleigh American City Business Journals
06:00AM  Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases ACCESSWIRE
Aug-13-19 09:00AM  Innovate Biopharmaceuticals, Inc. Announces First Patient Dosed in the First Phase 3 Clinical Trial for Patients with Celiac Disease GlobeNewswire
Aug-08-19 04:30PM  Innovate Biopharmaceuticals Reports Second Quarter 2019 Results and Corporate Updates GlobeNewswire +6.78%
Jul-19-19 11:48AM  Investors Who Bought Innovate Biopharmaceuticals (NASDAQ:INNT) Shares A Year Ago Are Now Down 82% Simply Wall St.
Jul-15-19 05:30PM  Innovate Biopharmaceuticals Announces Corporate Update and Expected Date for Second Quarter Earnings Release GlobeNewswire
Jun-25-19 07:24AM  Triangle pharma brings in new CFO looking for capital American City Business Journals -6.14%
Jun-24-19 07:00AM  Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer GlobeNewswire -6.56%
Jun-11-19 07:12AM  Triangle drugmaker launches historic trial for celiac disease American City Business Journals
Jun-10-19 08:01AM  Innovate Biopharmaceuticals Announces the Start of the First Phase 3 Clinical Trial in Celiac Disease GlobeNewswire
May-29-19 08:34AM  She left one Triangle public company to become CSO of another local public pharma American City Business Journals
May-20-19 09:45AM  Innovate Biopharmaceuticals Announces Presentation of Three Posters Focusing on the Molecular Biology and Pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego GlobeNewswire
May-09-19 08:01AM  Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego GlobeNewswire
May-01-19 04:30PM  Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering GlobeNewswire
04:47AM  Edited Transcript of INNT earnings conference call or presentation 29-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
Apr-29-19 03:10PM  Roller-coaster ride for Innovate's stock on Wall Street Monday American City Business Journals -14.74%
01:19PM  Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
07:35AM  Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR agonist, and Reports key first quarter 2019 financial results and operational highlights GlobeNewswire
Apr-26-19 12:59PM  Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details GlobeNewswire -6.86%
Apr-11-19 09:45AM  Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study GlobeNewswire
Apr-02-19 07:00AM  Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019 GlobeNewswire
Mar-26-19 09:32AM  Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models GlobeNewswire
Mar-20-19 02:41PM  Innovate Biopharma raises more cash, chases treatment for celiac disease American City Business Journals
Mar-19-19 07:45AM  Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights GlobeNewswire -10.48%
Mar-18-19 07:30PM  Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019 GlobeNewswire +15.89%
08:51AM  Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial GlobeNewswire
Mar-13-19 07:00PM  Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019 GlobeNewswire
Mar-06-19 09:00AM  Innovate Biopharmaceuticals Announces Presentation at Cowens 39th Annual Health Care Conference in Boston GlobeNewswire
Mar-01-19 05:33PM  Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019 GlobeNewswire
Feb-26-19 09:00AM  Innovate Biopharmaceuticals Schedules Conference Call to Provide Corporate and Operational Progress Updates GlobeNewswire
Feb-25-19 09:30AM  Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference GlobeNewswire
Feb-22-19 10:00AM  Innovate Biopharmaceuticals Announces a New Chief Executive Officer and Chief Medical Officer GlobeNewswire -11.54%
Feb-07-19 08:34AM  Innovate Biopharmaceuticals Announces Presentation at BIO CEO & Investor Conference GlobeNewswire
Dec-25-18 12:46PM  Could Innovate Biopharmaceuticals, Inc.s (NASDAQ:INNT) Investor Composition Influence The Stock Price? Simply Wall St.
Dec-17-18 08:00AM  Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019 GlobeNewswire -16.96%
06:50AM  Today's Research Reports on Trending Tickers: Innovate Biopharmaceuticals and Tenet Healthcare ACCESSWIRE
Dec-14-18 02:45PM  Healthcare Stocks That Could Weather the Market Volatility ACCESSWIRE +8.43%
Dec-11-18 06:55AM  Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Innovate Biopharmaceuticals ACCESSWIRE -7.74%
Dec-04-18 11:15AM  Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018 GlobeNewswire
Nov-26-18 06:00AM  Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P. GlobeNewswire
Nov-13-18 05:26PM  Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights GlobeNewswire
Nov-12-18 08:10AM  Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary Leaky Gut Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study GlobeNewswire -9.11%
Nov-05-18 09:15AM  Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference GlobeNewswire
Oct-31-18 09:00AM  Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Oct-29-18 07:00AM  Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study GlobeNewswire -11.01%
Oct-19-18 02:54PM  Innovate Biopharmaceuticals adds $5.2M to its coffers American City Business Journals
Oct-01-18 08:30AM  Innovate Biopharmaceuticals Announces Participation at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-18-18 10:04AM  When Can We Expect A Profit From Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? Simply Wall St.
Sep-06-18 07:30AM  Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City. GlobeNewswire -15.10%
Sep-05-18 08:50AM  Is the Options Market Predicting a Spike in Innovate Biopharmaceuticals (INNT) Stock? Zacks -14.29%
Sep-04-18 08:00AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune ACCESSWIRE +25.84%
Aug-31-18 10:00PM  Innovate Biopharmaceuticals Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018 GlobeNewswire +36.14%
Aug-23-18 07:00AM  Innovate Biopharmaceuticals Enters into an Agreement with Amarex Clinical Research for Data Management and Biostatistics for Phase 3 Celiac Disease Trial GlobeNewswire
Aug-15-18 07:10AM  Innovate Biopharmaceuticals Reports Second Quarter 2018 Earnings and Key Corporate Highlights GlobeNewswire
Aug-03-18 07:05AM  Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City GlobeNewswire
Jul-31-18 07:00AM  Innovate Biopharmaceuticals Enters into a Collaboration on Larazotides Effect on Improving the Microbiome of Children with EED with the University of Virginia School of Medicine GlobeNewswire
Jul-17-18 08:10AM  Todays Research Reports on Stocks to Watch: Genetic Technologies and Innovate Biopharmaceuticals ACCESSWIRE -8.17%
Jul-16-18 04:10PM  Why Innovate Biopharmaceuticals Stock Cratered Today Motley Fool -65.91%
Jun-28-18 07:00AM  Innovate Biopharmaceuticals Enters into an R&D Collaboration on Larazotides Corrective Effect on the Dysfunctional Intestinal Barrier and the Dysfunctional Microbiome in various Diseases with the University of Maryland School of Medicine GlobeNewswire
Jun-25-18 10:30AM  Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes GlobeNewswire +39.48%
Jun-13-18 07:10PM  Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D. GlobeNewswire
Jun-04-18 05:54PM  Is Innovate Biopharmaceuticals Incs (NASDAQ:INNT) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-31-18 07:02AM  Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on Friday, June 8, 2018, at 11:30AM GlobeNewswire
May-22-18 08:01AM  Innovate Biopharmaceuticals Scheduled to Present at BIO 2018 Convention in Boston on Tuesday, June 5, 2018, at 4:45PM GlobeNewswire
May-17-18 03:06PM  Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C. GlobeNewswire
May-16-18 09:10AM  Innovate Biopharmaceuticals Reports First Quarter 2018 Key Financial and Corporate Highlights GlobeNewswire +6.90%
May-09-18 02:07PM  Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference GlobeNewswire -7.76%
Apr-10-18 06:31PM  Who Owns Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? Simply Wall St.
Apr-05-18 06:03AM  Innovate Biopharmaceuticals, Inc. to Present at the H.C. Wainwright Annual Global Life Sciences Conference on April 9, 2018 GlobeNewswire
Mar-24-18 12:01AM  [$$] Charting the Market Barrons.com
Mar-13-18 07:32AM  Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire -9.69%
Mar-07-18 07:32AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET GlobeNewswire -10.34%
Mar-06-18 08:20AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical ACCESSWIRE -16.18%
Feb-13-18 11:19AM  How Does Innovate Biopharmaceuticals Inc (NASDAQ:INNT)s Prospect Stack Up Next To Its Healthcare Peers? Simply Wall St.
Feb-07-18 10:30AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:30PM ET GlobeNewswire -11.04%
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.